Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.49 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5339319 | 0.91 | HTR1A (0.55) | GPR119ACHETLR9TLR7CKS1B | |
| SCHEMBL2385047 | 0.87 | GPR119 (0.64) | GPR119ACHETLR9TLR7CKS1B | |
| SCHEMBL5346345 | 0.83 | SMN1; SMN2 (0.47) | GPR119SMN1; SMN2ACHETLR9TLR7 | |
| SCHEMBL4921870 | 0.82 | HTR6 (0.61) | GPR119ACHETLR9TLR7CKS1B | |
| SCHEMBL2386443 | 0.81 | GPR119 (0.68) | GPR119ACHETLR9TLR7 | |
| SCHEMBL8139691 | 0.80 | TSHR (0.54) | GPR119SMN1; SMN2ACHECKS1BSKP1 | |
| SCHEMBL1448446 | 0.80 | GPR119 (1.00) | GPR119 | |
| SCHEMBL2384061 | 0.80 | GPR119 (0.63) | GPR119ACHETLR9TLR7 | |
| SCHEMBL5373351 | 0.79 | SMARCA2 (0.50) | GPR119SMN1; SMN2ACHECKS1BSKP1 | |
| SCHEMBL5338019 | 0.79 | L3MBTL1 (0.57) | GPR119SMN1; SMN2ACHECKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1608373-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083235-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | GPR119 686/4885SMN1; SMN2 3129/4885ACHE 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.